This end-of-summer seminar takes a longitudinal view of AI across the full drug development pipeline — from the earliest stages of target identification and validation through to clinical trial design and execution. Through in-depth case studies and expert presentations, participants will examine where AI is delivering genuine, measurable value and where significant challenges remain.
The second half of the session turns to the future: an open, structured discussion to identify the topics, themes, and use cases that should shape the LSAIE programme in 2027. This is your opportunity to help set the agenda — ensuring the programme remains grounded in the real priorities of the life science community.
All members are encouraged to come prepared with use cases, questions, and perspectives from their own organisations.
Register below